Scientists test new prostate disease drug

Mar 27, 2008

A Canadian-headquartered biopharmaceutical company is conducting the second Phase 3 study of a new drug designed to treat prostate disease.

Aeterna Zentaris Inc. said the double-blind study to be conducted in Europe will test the clinical effectiveness of cetrorelix, a luteinizing hormone-releasing drug for the treatment of benign prostatic hyperplasia, or BPH -- a non-cancerous enlargement of the prostate that causes disturbances in urination.

In the second Phase 3 study, 400 male patients will enter a four-week, no-treatment observation period and then be randomly assigned to either receive cetrorelix or a placebo. Effectiveness will based on a test that measures the severity and stability of voiding prostate symptoms.

The company's first study of the effectiveness of cetrorelix began in April 2007 and is continuing in Canada, Europe and the United States.

Copyright 2008 by United Press International

Explore further: First clinical trial for new skin wound-healing compound is a success

add to favorites email to friend print save as pdf

Related Stories

One Codex in open beta for genomic data search

2 hours ago

Data, data everywhere and now as ever researchers need the best tools to make the data useful. In medicine, searching through genomic data can take some time. A startup called One Codex hopes to make difference ...

After breakups, newspapers seek path forward

3 hours ago

Following an unprecedented series of spinoffs by major US media companies, the print news industry now faces a rocky future without financial support from deep-pocketed parent firms.

Recommended for you

Boxed warnings are common in novel therapeutics

Aug 19, 2014

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

Aug 19, 2014

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

User comments : 0